Progress of human epididymis protein 4 and carbohydrate antigen 125 in epithelial ovarian cancer
10.3760/cma.j.issn.1006-9801.2019.01.014
- VernacularTitle:人附睾蛋白4和糖类抗原125在卵巢上皮性癌中的研究进展
- Author:
Meng TONG
1
;
Lixin SUN
Author Information
1. 山西医科大学研究生院
- Keywords:
Epithelial ovarian cancer;
Human epididymis protein 4;
Carbohydrate antigen 125;
Diagnosis;
Prognosis
- From:
Cancer Research and Clinic
2019;31(1):58-61
- CountryChina
- Language:Chinese
-
Abstract:
Epithelial ovarian cancer (EOC) has the highest mortality rate among the gynecological malignancies. Because of its early symptoms are not obvious and lack of effective screening methods, more than 70％ patients have been diagnosed at late stage (stage Ⅲ-Ⅳ). Although the 5-year progression-free survival (PFS) of EOC was prolonged with the improvement of treatment methods, its prognosis was still poor, and 50％-95％ patients relapsed within 2 years after treatment. Human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) are widely used in the evaluation of diagnosis, treatment efficacy and prognosis of EOC, but the evaluation effect of both HE4 and CA125 is rarely reported. Therefore, it is necessary to summarize the research progress of HE4 and CA125 in evaluating the diagnosis, treatment efficacy and prognosis of EOC.
